What type of study is this?

September 17, 2025Frontiers in ImmunologyOpen Access

225Actinium-armed antibody targeting CCR8+ regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models

View Full Paper

Ask AI

Bookmark

Authors

Radioimmunotherapy shows synergistic effects with immunotherapy in colorectal cancer, indicating potential novel treatment options.

Combining actinium-anti-CCR8 therapy with immunotherapy significantly improves tumor rejection in CRC models.
The study highlights enhanced activity of effector CD8+ T cells and M1 macrophages post-treatment with actinium-anti-CCR8.
Safety assessments included complete blood counts and blood chemistry in treated mice to monitor adverse effects.
Immunohistochemical analysis confirmed the depletion of CCR8+ regulatory T cells within tumors after treatment.

Frank et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark